A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]
Latest Information Update: 23 May 2024
At a glance
- Drugs Leronlimab (Primary)
- Indications Cognition disorders; COVID-19 respiratory infection; Dyspnoea; Fatigue; Sleep disorders
- Focus Therapeutic Use
- Sponsors CytoDyn
- 16 May 2024 According to a CytoDyn media release, the clinical endpoint data from the Long COVID trial (CD 15) was recently published in the Journal of Infection. All publications will be available on the Company's website soon after publication.
- 01 Dec 2021 According to a CytoDyn media release, the company has submitted for peer review yesterday.
- 30 Jul 2021 Status changed from active, no longer recruiting to completed.